When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
IOBT - IO Biotech posts positive data from metastatic melanoma therapy trial
IO Biotech Inc.
IO Biotech (NASDAQ:IOBT) announced data from Phase 1/2 study of IO102-IO103 in Combination with Nivolumab in Metastatic Melanoma. The company said the data from the trial showed three-year survival probability of 73% in patients with metastatic melanoma. IOBT reported the median progression free survival was 25.3 months. Shares of the company rose +3% after the bell.